Article
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.
The Journal of antimicrobial chemotherapy - 1 Apr 2016
Lambert-Niclot S, George E C, Pozniak A, White E, Schwimmer C, Jessen H, Johnson M, Dunn D, Perno C F, Clotet B, Plettenberg A, Blaxhult A, Palmisano L, Wittkop L, Calvez V, Marcelin A G, Raffi F
Abstract excerpt
OBJECTIVES: To describe the pattern of drug resistance at virological failure in the NEAT001/ANRS143 trial (first-line treatment with ritonavir-boosted darunavir plus either tenofovir/emtricitabine or raltegravir). METHODS: Genotypic testing was performed at baseline for reverse transcriptase (RT) and protease genes and for RT, protease and integrase (IN) genes for patients with a confirmed viral load (VL) >50...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.